Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer. the role of clinical response (Q44433157)

2 December 2017

title

Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer. the role of clinical response (English)

1 reference

2 December 2017

1 reference

Pierga JY

1

1 reference

2 December 2017

Mouret E

2

1 reference

2 December 2017

Laurence V

3

1 reference

2 December 2017

Diéras V

4

1 reference

2 December 2017

Savigioni A

5

1 reference

2 December 2017

Beuzeboc P

6

1 reference

2 December 2017

Dorval T

7

1 reference

2 December 2017

Palangié T

8

1 reference

2 December 2017

Jouve M

9

1 reference

2 December 2017

Pouillart P

10

1 reference

2 December 2017

publication date

1 May 2003

1 reference

European Journal of Cancer

2 December 2017

published in

1 reference

2 December 2017

volume

39

1 reference

2 December 2017

issue

8

1 reference

2 December 2017

page(s)

1089-1096

1 reference

Primary chemotherapy for early and advanced breast cancer

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900069-8

7 January 2021

Neoadjuvant chemotherapy in women with invasive breast carcinoma: conceptual basis and fundamental surgical issues

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900069-8

7 January 2021

Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900069-8

7 January 2021

Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900069-8

7 January 2021

Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900069-8

7 January 2021

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900069-8

7 January 2021

Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS)

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900069-8

7 January 2021

Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900069-8

7 January 2021

Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900069-8

7 January 2021

Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900069-8

7 January 2021

Primary chemotherapy for operable breast cancer: incidence and prognostic significance of ipsilateral breast tumor recurrence after breast-conserving surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900069-8

7 January 2021

Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900069-8

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900069-8

7 January 2021

Preoperative chemotherapy: a model for studying the biology and therapy of primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900069-8

7 January 2021

Preoperative (neoadjuvant) chemotherapy in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900069-8

7 January 2021

Breast tumour response to primary chemotherapy predicts local and distant control as well as survival

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900069-8

7 January 2021

Primary systemic therapy for operable breast cancer--10-year survival data after chemotherapy and hormone therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900069-8

7 January 2021

Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900069-8

7 January 2021

Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900069-8

7 January 2021

Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900069-8

7 January 2021

Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900069-8

7 January 2021

Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900069-8

7 January 2021

Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900069-8

7 January 2021

Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900069-8

7 January 2021

Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900069-8

7 January 2021

High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900069-8

7 January 2021

Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900069-8

7 January 2021

A critique of the eleven randomised trials of high-dose chemotherapy for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900069-8

7 January 2021

Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900069-8

7 January 2021

10.1016/S0959-8049(03)00069-8

Identifiers

DOI

1 reference

2 December 2017

1 reference